FDA
-
-
-
-
-
-
-
Anteris receives $90 million strategic investment from Medtronic
-
-
-
-
-
-
-
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
-
-
-
-
-
-
-
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
-
-
-
-
-
-
-
Anteris Technologies Global (AVR) Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV
-
-
-
-
-
-
-
Anteris Technologies Receives FDA Clearance to Initiate Early Feasibility Study for its Novel TAVR Product, DurAVR™
-
-
-
-
322,885 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

